CASE SNAPSHOT 06

Capital & Partnering Readiness

Investors and partners do not buy a protocol. They buy a credible risk-adjusted path to decision-grade evidence and future value.

CONTEXT

The situation

Capital raise and partnering discussions required a coherent, diligence-ready clinical development, evidence, and risk narrative.

DECISION CHALLENGE

Regulatory path, pivotal evidence, and payer logic were not fully integrated
Competitive landscape at launch was not reflected in the differentiation strategy
Communications and publication planning were not aligned with value inflection points
Board and investor materials needed sharper risk logic and mitigation structure

OUR INTERVENTION

Built evidence architecture with clinical, regulatory, HTA/HEOR, commercial, and operational decision gates
Produced risk map and mitigation plan aligned to investor and partner diligence questions
Integrated competitive, payer, and regulatory logic into the development narrative
Aligned publications and communications with key data milestones

OUTCOMES

Improved diligence readiness
Stronger credibility at financing and partnering inflection points
Clearer explanation of risk, value, and development optionality
Contributed to >$50M in financing and value-inflection discussions across engagements

STRATEGIC IMPLICATION

RELATED CAPABILITY

Turn clinical, regulatory, payer and execution risk into a decision-grade development and diligence narrative.

A SIMILAR DECISION?

Bring the live decision, the next hard milestone and the uncertainty that is currently exposed.